Skip to main content

GamaSTAN S/D Disease Interactions

There is 1 disease interaction with GamaSTAN S/D (immune globulin intramuscular).

Major

Immune globulin IV/SQ/IM (applies to GamaSTAN S/D) thrombosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hyponatremia, Diabetes Mellitus, Cardiovascular Disease, Polycythemia, History - Thrombotic/Thromboembolic Disorder

Thrombosis has been reported after treatment with immune globulin products. In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.

References

  1. "Product Information. Gamunex-C (immune globulin intravenous and subcutaneous)." Talecris Biotherapeutics (2011):
  2. "Product Information. Gammaplex (immune globulin intravenous)." Bio Products Laboratory (2016):
  3. "Product Information. Flebogamma (immune globulin intravenous)." Grifols USA LLC (2016):
  4. "Product Information. Gamastan S/D (immune globulin intramuscular)." Grifols Therapeutics (2018):
  5. "Product Information. Cuvitru (immune globulin subcutaneous)." Baxter Healthcare Corporation (2018):
View all 5 references

GamaSTAN S/D drug interactions

There are 22 drug interactions with GamaSTAN S/D (immune globulin intramuscular).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer